



Figure S1 Six-week landmark analysis for overall survival in patients with or without systemic cancer therapy after the 1st episode of ICI-related ILD. ILD, interstitial lung disease; OS, overall survival; CI, confidence interval; NE, not evaluable.

Table S1 Baseline characteristics of patients with and without the recurrent ICI-related ILD

Characteristic	Recurrent ICI-related ILD		No recurrent ILD	p Value
	(N=8)		(N=8)	
Median age (range), years	65 (62–73)		65 (45–74)	0.33 ^a
Sex, n (%)	Male	7 (88)	5 (63)	0.25 ^b
	Female	1 (12)	3 (37)	
Smoking status, n (%)	Current or former	7 (88)	6 (75)	0.52 ^b
	Never	1 (12)	2 (25)	
ECOG-PS, n (%)	0	1 (12)	3 (37)	0.39 ^b
	1	5 (63)	5 (63)	
	≥2	1 (12)	0	
	Unknown	1 (12)	0	
Disease stage, n (%)	IIIB	0	0	0.05 ^b
	IV	2 (25)	6 (75)	
Histology, n (%)	Relapse after local therapy	6 (75)	2 (25)	1 ^b
	Adenocarcinoma	2 (25)	2 (25)	
	Squamous carcinoma	5 (63)	5 (63)	
	Others	1 (12)	1 (12)	
Line of anti-PD-1 therapy, n (%)	1	2 (25)	0	0.31 ^b
	2	4 (50)	5 (63)	
	3	2 (25)	3 (37)	
PD-L1 expression, n (%)	< 1	1 (12)	0	0.16 ^b
	1-49%	0	0	
	> 50%	2 (25)	0	
	Unknown	5 (63)	8 (100)	
Anti-PD-1 therapy, n (%)	Nivolumab	6 (75)	8 (100)	0.13 ^b
	Pembrolizumab	2 (25)	0	
Response to anti-PD-1 therapy	CR	1 (12)	1 (12)	0.86 ^b
	PR	2 (25)	2 (25)	
	SD	3 (37)	3 (37)	
	PD	1 (12)	2 (25)	
	NE	1 (12)	0	
Baseline interstitial lung abnormality, n (%)	2 (25)		1 (12)	0.55 ^a
Grade of initial ILD	1-2	4 (50)	7 (88)	0.11 ^b
	3-4	4 (50)	1 (12)	
Radiologic features, n (%)	COP-like	4 (50)	5 (63)	0.61 ^b
	GGO	4 (50)	3 (37)	
	Not otherwise specified	0	0	
Systemic steroid use, n (%)	7 (88)		6 (75)	0.55 ^a
Time to the ILD, days (range)	24 (5-523)		50.5 (1-295)	0.56 ^a

Differences between groups were identified using ^astudent's *t* test or ^bChi-Square test. ICI, immune checkpoint inhibitor; ILD, interstitial lung disease; ECOG, Eastern Cooperative Oncology Group; PS, performance status; PD-1, programmed cell death-1; PD-L1, PD-ligand 1; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable; COP, cryptogenic organizing pneumonia; GGO, ground glass opacity.